B
Bull
Bull · 25%VTYX
$3.97
Szenariopreis
$14.000
+0.020 (+0.14%)Zum Schluss
Loading chart…
- High
- 14.000
- Open
- 13.990
- VWAP
- 14.00
- Vol
- 5.45M
- Mkt Cap
- 168.49M
- Low
- 13.990
- Amount
- 76.27M
- EV/EBITDA, TTM
- 0.00
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.
AI analysis of Ventyx Biosciences Inc (VTYX)
holdVentyx Biosciences (VTYX) is not a suitable buy for a beginner, long-term investor at this time. The stock is set to be acquired by Eli Lilly for $14 per share in cash, which caps its upside potential. With no significant catalysts, weak financial performance, and no trading signals from Intellectia Proprietary Trading Signals, holding the stock is the most logical action.
Bewertungskennzahlen
The current forward P/E ratio for Ventyx Biosciences Inc (VTYX) is -5.51, compared to its 5-year average forward P/E of -5.56.
Alphio AI Price Scenarios for VTYX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding VTYX
Event-Zeitleiste
News
4.502-10FoolEli Lilly's Strategic Moves to Address Patent Cliff Risks
7.502-10NASDAQ.COMEli Lilly's GLP-1 Drug Demand Soars Amid Future Concerns
8.502-05BusinesswireInvestigation into Proposed Sale of Ventyx Biosciences to Eli Lilly
8.502-05GlobenewswireHalper Sadeh LLC Investigates Multiple Companies for Potential Violations
8.502-05GlobenewswireMonteverde Law Firm Investigates Multiple Mergers and Acquisitions
VTYX FAQ — answered by Alphio AI
Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Ventyx Biosciences (VTYX) is not a suitable buy for a beginner, long-term investor at this time. The stock is set to be acquired by Eli Lilly for $14 per share in cash, which caps its upside potential. With no significant catalysts, weak financial performance, and no trading signals from Intellectia Proprietary Trading Signals, holding the stock is the most logical action.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.